Cronos Group Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY Revenue (est.)
$278.8Mnext fiscal year
FY EPS (est.)
$0.22next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
| Q4 2026 and Full-Year Earnings Release | 25 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Consolidated Net Revenue Quarterly45.2MTarget: Sustainable quarterly growth driven by international expansion and Canadian vape leadership
Adjusted EBITDA Quarterly5.1MTarget: Maintain positive Adjusted EBITDA trajectory
Total Cash and Cash Equivalents Quarterly821.9MTarget: Strategic capital allocation including share repurchases and M&A
Spinach Vape Market Share in Canada Quarterly9.8%Target: Maintain #100 market share position in Canada%
Watch Items
- Acquisition of CanAdelaar B.V. in the NetherlandsTrigger: Extended long-stop date of September 9, 2026Action: Monitor regulatory clearances and license confirmations from Dutch authorities to establish a European adult-use footprint.
- U.S. Cannabis Rescheduling and Regulatory ReformTrigger: Official DEA rescheduling of cannabis to Schedule IIIAction: Evaluate optimal entry points and partnerships in the U.S. market leveraging the Altria relationship.
- Israeli Medical Cannabis Market DynamicsTrigger: Geopolitical stability and local competitive pricing pressuresAction: Track PEACE NATURALS brand performance and supply chain continuity to sustain its market-leading position.
Research as of 19 Jun 2026